Ocular Migraine: A Deep Dive into What It Is, What It Isn’t, and Why Clarity Is Crucial

Introduction

Have you ever experienced a sudden burst of flashing lights, a shimmering zigzag arc expanding in your vision, or a temporary blind spot that unnervingly obscures your view? If so, you might have used the term “ocular migraine” to describe it. It’s a common, intuitive phrase, but it is not a precise medical diagnosis, a fact that causes significant confusion for patients and clinicians alike.

In the vast majority of cases, what people are experiencing is a specific neurological event known as migraine with aura. On very rare occasions, the symptoms might point to retinal migraine, a distinct condition affecting only one eye. Telling them apart is not just a matter of semantics; it is fundamental for receiving the correct diagnosis, managing the condition effectively, and, most importantly, recognising the rare instances when these visual disturbances signal a medical emergency like a stroke or retinal damage [¹ | Headache Classification Committee, 2018, ICHD-3].

This article will demystify the term “ocular migraine.” We will explore what the symptoms mean, delve into the science behind them, explain the official diagnostic terms, and provide a comprehensive guide to management within the Australian context. Our goal is to replace confusion with clarity, empowering you to have more effective conversations with your healthcare providers and take control of your health.

Plain language: Aura = a temporary and reversible neurological symptom that occurs during a migraine.

Medically reviewed by Dr. Jason Ray, September 12, 2025

Why the Term “Ocular Migraine” Creates Confusion

The Brain vs. The Eye: Where the Problem Really Lies

The word “ocular” points to the eye. This leads to a logical but incorrect assumption: that the problem originates within the eyeball itself. While the symptoms are visual, their source is almost always the brain. Specifically, they arise from a wave of electrochemical activity sweeping across the visual cortex—the part of your brain at the back of your head responsible for processing everything you see. In other words, your eye is sending information perfectly, but the visual processing centre of the brain is mixing up the messages.

Groundbreaking functional MRI (fMRI) studies, including a foundational paper from 2001, have visually captured this brain activity, confirming that the aura experience directly maps to a phenomenon in the brain, not a problem with the eye’s structure [² | Hadjikhani et al., 2001, fMRI aura]. More recent reviews and imaging studies consistently reinforce this brain-based origin, showing how this wave of activity, called cortical spreading depression, alters blood flow and neuronal function temporarily [³ | Friedman, 2019, Visual auras] [⁴ | Viana et al., 2019, Visual aura review].

The Risks of an Imprecise Label

Using a vague term like “ocular migraine” isn’t just inaccurate; it can have real-world consequences:

Over-investigation for Benign Cases: A patient describing “ocular migraine” might be sent for repeated, expensive, and stressful ophthalmology work-ups for what is a classic migraine with aura.
Under-investigation for Emergencies: Conversely, the label can create a false sense of security. A person experiencing true, sudden vision loss in one eye—a potential sign of a stroke or retinal artery occlusion—might dismiss it as “just my ocular migraine,” delaying life-saving emergency treatment.

The difference between a brain-generated aura (affecting both eyes) and a true monocular (one-eyed) visual disturbance is the single most important diagnostic clue, and the term “ocular migraine” blurs this critical distinction [³ | Friedman, 2019, Visual auras].

What Do People Mean by “Ocular Migraine”? A Guide to Visual Aura

When people say “ocular migraine,” they are almost always describing the fascinating and sometimes worrying symptoms of a visual aura. This is the most common type of migraine aura, experienced by over 90% of people who have migraine with aura [⁴ | Viana et al., 2019, Visual aura review].

The Spectrum of Symptoms: From Flashing Lights to Blind Spots

Visual aura is not a single symptom but a rich and varied experience that typically evolves over several minutes. The International Classification of Headache Disorders (ICHD-3) outlines the features, which can be “positive” or “negative” [¹ | Headache Classification Committee, 2018, ICHD-3].

Positive Symptoms (seeing things that aren’t there):

Scintillations: This is the perception of bright, flashing, or flickering lights.
Fortification Spectra (or Teicopsia): This is the classic, textbook aura. It often starts as a small, shimmering, or greyish spot near the centre of vision. Over 5 to 30 minutes, it slowly expands into a C-shaped or zigzagging arc of shimmering, silvery, or coloured light, often described as looking like the battlements of a medieval fort (hence “fortification”) – or altenarively, like the kalaeidoscope of a children’s toy.
Geometric Shapes: Patients may report seeing lines, waves, or other patterns.

Negative Symptoms (areas of missing vision):

Scotoma: This is a blind spot. Often, the expanding shimmering edge of a fortification spectrum leaves a scotoma in its wake. This can be profoundly disorienting, making activities like reading or recognising faces impossible.
Hemianopia: A loss of one half (left or right) of the visual field.

Plain language: Scotoma = a blind spot in your vision.

The aura typically lasts less than 60 minutes and is fully reversible, meaning vision returns completely to normal. A headache may follow the aura, usually within an hour, but for some people, the aura can occur without any subsequent headache. This is known as acephalgic migraine or “silent migraine,” and it can become more common as people age [⁴ | Viana et al., 2019, Visual aura review].

The Critical Test: Is It in One Eye or Both?

This simple test is the most powerful tool you have to help a doctor understand what’s happening. During an episode of visual disturbance:

Cover your left eye. Look at your surroundings. Is the visual disturbance (the zigzags, the blind spot) still there?
Now cover your right eye. Look again. Is the disturbance still present?

If the visual phenomenon is present regardless of which eye is covered, it means the signal is being processed incorrectly by your brain. Your brain creates a single visual field from the input of both eyes, so a problem in the visual cortex will appear in that combined field. Even if the disturbance seems to be on the “left side,” it’s actually in the left half of the visual field of both eyes. This is the hallmark of migraine with aura.

If the disturbance disappears completely when you cover one specific eye, that means the problem may be located within that uncovered eye. While this may relate to the less common retinal migraine, other serious eye conditions also need to be considered by your doctor [³ | Friedman, 2019, Visual auras].

“Ocular Migraine” is Not an Official Diagnosis

What the “Headache Bible” (ICHD-3) Says

In the world of neurology and headache medicine, the diagnostic gold standard is the International Classification of Headache Disorders, which is currently in its third edition (ICHD-3). This meticulously detailed document, published by the International Headache Society, provides strict criteria for every recognised headache disorder to ensure that a diagnosis of “migraine” in Sydney means the same thing as it does in London or Tokyo [¹ | Headache Classification Committee, 2018, ICHD-3].

If you search the ICHD-3 for “ocular migraine,” you will not find it. The term is considered obsolete and imprecise. Instead, the ICHD-3 provides clear, criteria-based diagnoses for the conditions people are actually experiencing:

1.2 Migraine with aura (and its sub-forms, like 1.2.1 Migraine with typical aura)

1.2.3 Retinal migraine

Why Clear Terminology is a Doctor’s Best Tool

Using these official terms is essential for effective medical care. When a patient says, “I have zigzag lines in both eyes that last for 20 minutes before my headache starts,” a doctor can confidently diagnose 1.2.1 Migraine with typical aura. This diagnosis immediately informs the treatment plan and the type of reassurance or further testing required.

In contrast, the term “ocular migraine” is a dead end. It doesn’t tell the doctor whether the symptom is in one eye or two, how long it lasts, or what it looks like—all of which are critical pieces of the diagnostic puzzle.

Migraine with Aura: The Most Common Explanation

As we’ve established, what most people call “ocular migraine” is migraine with aura. This is a common phenomena, affecting roughly 20-30% of people who experience migraine. Population-based studies, such as a large Korean study and the recent Danish REFORM study, confirm the significant prevalence and impact of visual aura [⁵ | Kim et al., 2022, Visual aura prevalence] [⁶ | Thomsen et al., 2024, REFORM study].

Understanding the Visual Experience in Detail

The classic aura, or fortification spectrum, is remarkable in its stereotyped progression. It often begins as a barely perceptible shimmer or a small patch of blurred or pixelated vision, called a paracentral scotoma. Over minutes, this area slowly drifts and expands. The leading edge typically becomes a vibrant, shimmering, zigzagging line. As this arc grows, it may seem to “march” across the visual field, leaving behind an area of blurred or completely missing vision (the scotoma). The entire event unfolds methodically, usually over 20 to 30 minutes, before fading away.

The Brain Wave: Cortical Spreading Depression (CSD)

The biological basis for this mesmerising visual display is a phenomenon called cortical spreading depression (CSD). Imagine a ripple spreading slowly across a still pond. CSD is a similar—albeit much more complex—wave of intense nerve cell activity that moves across the surface of the brain (the cortex) at a rate of approximately 3-5 millimetres per minute [² | Hadjikhani et al., 2001, fMRI aura]. This speed perfectly matches the slow, marching progression of the visual aura symptoms that patients describe.

Plain language: CSD = a slow wave of electrical changes in the brain’s visual cortex.

This wave involves a massive release of neurotransmitters (like glutamate) and ions (like potassium) from neurons. This initial burst of activity is what likely causes the “positive” symptoms of aura, like the flashing and shimmering. This intense activity is metabolically demanding, and it is followed by a prolonged period of suppressed nerve cell activity and changes in local blood flow, which likely corresponds to the “negative” symptom of the scotoma or blind spot [¹⁴ | Ashina et al., 2021, NRDP Primer]. CSD is considered the central mechanism of migraine aura and is a major focus of ongoing research.

The left and right visual cortex and its location in our brains

[Illustration: The left and right visual cortex and its location in our brains]
Source: Perkins. Org https://www.perkins.org/the-visual-pathway-from-the-eye-to-the-brain/

Clinical Hallmarks: What Defines a Typical Aura

According to the ICHD-3, a diagnosis of “migraine with typical aura” requires at least two attacks that meet specific criteria, which precisely describe the experience:

Fully reversible visual, sensory, or speech symptoms. No lasting deficit.
Gradual development. The symptoms should develop over at least 5 minutes. This is a key feature that distinguishes it from a stroke, which is typically sudden.
Duration of 5 to 60 minutes. An aura lasting longer than an hour is considered atypical and may require further investigation to rule out other causes.
At least one symptom is unilateral (on one side). For visual aura, this means it affects the left or right half of the visual field.
The aura is accompanied, or followed within 60 minutes, by a headache.

While knowing the clinical hallmarks is helpful in understanding migraine aura, it is important to discuss your presentation with your doctor to obtain a diagnosis as there are no absolute rules in medicine. In particular if you have for the first time the sudden onset of neurological symptoms, it is important to be assessed in the emergency department. Remember the stroke acronym:

Face – facial droop

Arms: arm or leg weakness or symptoms

Speech: slurred or confused speech

Time: act quickly!

Remember that a migraine aura is usually stereotyped – if it is usually a visual aura for you, then it will often be the same. If it is a new or different symptom, it may be a stroke and needs prompt assessment.

Retinal Migraine: The True One-Eyed Aura (and Why It’s So Rare)

Now we turn to the much rarer and diagnostically challenging condition: retinal migraine. This is the only official diagnosis that truly involves monocular (one-eyed) visual symptoms linked to migraine.

Defining a Diagnosis of Exclusion

Retinal migraine is defined by the ICHD-3 as recurrent attacks of fully reversible, monocular visual phenomena (like flickering, blind spots, or temporary blindness) associated with a migraine headache [¹ | Headache Classification Committee, 2018, ICHD-3]. The most critical part of this definition is that all other causes for these symptoms must be ruled out.

This makes it a “diagnosis of exclusion.” A doctor cannot confidently diagnose retinal migraine until they have performed a thorough assessment to ensure the symptoms aren’t caused by something more common or sinister, such as a small clot travelling to the eye (amaurosis fugax), retinal artery or vein occlusion, or inflammation of the optic nerve [⁷ | Chong et al., 2021, Retinal migraine].

How It Differs Critically from Migraine with Aura

The following table summarises the essential differences. Getting this right is paramount for safety.

Feature	Migraine with Aura (Common)	Retinal Migraine (Extremely Rare)
Origin	Brain (Visual Cortex)	Eye (Retina or its circulation)
Eyes Affected	Both eyes (a homonymous field defect)	One eye only (monocular)
How to Test	Disturbance persists with either eye covered	Disturbance vanishes when the affected eye is covered
Typical Symptoms	Gradual spread of zigzags, shimmering, expanding scotoma	Flickering, dimming, “looking through cracked glass,” or complete but temporary blindness in one eye
Mechanism	Cortical Spreading Depression (CSD)	Less well described – believed to be vasospasm (constriction of blood vessels) or a CSD-like event in the retina itself

The Underlying Concern: Retinal Health

While retinal migraine attacks are temporary by definition, there is a small but documented risk of permanent vision loss in the affected eye due to complications like retinal infarction (tissue death from lack of blood supply). This is why a new episode of monocular vision loss should always be treated as a medical emergency until proven otherwise, and why people with a confirmed diagnosis of retinal migraine require careful management and follow-up with both a neurologist and an ophthalmologist [⁷ | Chong et al., 2021, Retinal migraine].

Other Conditions Mistaken for “Ocular Migraine”

New or atypical visual disturbances demand a careful differential diagnosis. Dismissing something serious as “just a migraine” is a dangerous mistake. Here are key conditions that must be considered.

A list of other conditions that may be considered are below, but it is critical you speak with your doctor so that they can support you and make a diagnosis. This may include:

Calling an ambulance (‘000’ in Australia) if you are experiencing acute symptoms of a stroke
Calling nurse on call (depending on your location) or after-hours service if after hours you are uncertain of what to do
Speaking to your treating doctor

Transient Ischaemic Attack (TIA): A “Brain Attack”

A TIA is a temporary blockage of a blood vessel supplying the brain or retina. It causes stroke-like symptoms that resolve, but it is a major warning sign that a full-blown stroke could be imminent. The Australian and New Zealand Living Clinical Guidelines for Stroke Management state unequivocally that a TIA is a medical emergency requiring urgent assessment, as the highest risk of stroke is in the first 48 hours [⁸ | ANZ Living Stroke Guidelines, 2022, TIA emergency].

How it differs from aura: TIA symptoms are typically sudden and negative. Instead of building zigzags, a patient might describe a “curtain coming down” or a “grey-out” of vision in one eye (known as amaurosis fugax). It happens in an instant, unlike the 5-20 minute gradual development of a typical aura.

Retinal Artery Occlusion & Retinal Detachment

These are ophthalmological emergencies that can lead to permanent blindness if not treated immediately.

Central Retinal Artery Occlusion (CRAO): This is a “stroke in the eye,” caused by a blockage of the main artery feeding the retina. It causes sudden, profound, painless vision loss in one eye [⁹ | Pula & Kattah, 2016, Transient vision loss].

Retinal Detachment: The light-sensitive retinal layer pulls away from the back of the eye. Patients often report a sudden increase in floaters, flashes of light (photopsia), and then a “shadow” or “curtain” that obscures part of their vision.

Optic Neuritis and Occipital Lobe Seizures

Optic Neuritis: This is inflammation of the optic nerve, the cable connecting the eye to the brain. It is often an early sign of multiple sclerosis (MS). Key symptoms include vision loss or blurring that may develop over several days, colours appearing washed out or desaturated, and often, pain when moving the eye [¹⁰ | Petzold et al., 2022, Optic neuritis].

Occipital Lobe Seizures: Seizures originating in the brain’s visual cortex can cause visual phenomena. These are typically very brief (seconds to a couple of minutes), often consisting of bright, multi-coloured, circular patterns, and can be followed by a post-ictal headache, which can be confused with migraine [⁴ | Viana et al., 2019, Visual aura review].

Red Flags: When to Seek Urgent Medical Care

Your visual system is precious. While a typical, recurring migraine aura in someone with an established diagnosis is not an emergency, you should seek immediate medical attention (by calling Triple Zero (000) or going to the nearest emergency department) for any of the following:

Sudden Vision Loss: Any abrupt loss of vision, especially in one eye (“a curtain came down”).
Symptoms >60 Minutes: Visual disturbances that last longer than one hour.
“First or Worst”: The very first time you experience aura-like symptoms, or if the headache is the “worst of your life.”
Atypical Symptoms: Visual symptoms that are always on the same side of the body with every attack, or that are different from your usual pattern.
Accompanied by other Neurological Signs: Any visual disturbance that occurs with other stroke symptoms, such as facial droop, arm or leg weakness, numbness, or difficulty with speech or understanding (remember the F.A.S.T. acronym: Face, Arms, Speech, Time).

Australian general practice and stroke guidelines are clear: any suspected TIA or new, persistent, or atypical visual loss warrants same-day assessment [⁸ | ANZ Living Stroke Guidelines, 2022, TIA emergency] [¹¹ | RACGP AJGP, 2021, Transient vision loss].

Getting a Proper Diagnosis: A Step-by-Step Guide

Preparing for Your Doctor’s Appointment

A clear history is the most valuable diagnostic tool. Before your appointment, try to document the answers to these questions. Consider using a diary or an app or a notebook.

The Cover Test: Did you perform it? Was the disturbance in one eye or both?
Description: What did it look like? Try to draw it. Was it black and white or coloured? Shimmering, flashing, or static? Did it move or expand?
Timeline: How long did it take to develop? How long did the entire visual event last? Did a headache follow? If so, when did it start, and how long did it last?
Associated Symptoms: Did you experience any other symptoms like numbness, tingling, weakness, or difficulty speaking?
Triggers: What were you doing just before it started? Were you stressed, tired, or exposed to bright lights?
History: Is this the first time? Do you have a personal or family history of migraine?

The Roles of Your GP, Optometrist, and Neurologist

A diagnosis often involves a team approach:

General Practitioner (GP): Your GP is your first port of call. They will take a detailed history, perform a basic neurological examination, check your blood pressure, and decide if your symptoms sound like a typical migraine with aura or if they warrant urgent referral.

Optometrist/Ophthalmologist: For any new visual disturbance, an eye exam is crucial to rule out physical eye disease. They will check your visual acuity and visual fields and perform a dilated fundus exam to look at your retina and optic nerve at the back of the eye.

Neurologist: If your symptoms are atypical, severe, or not responding to initial treatment, your GP will refer you to a neurologist. They are specialists in diagnosing and managing disorders of the brain, including migraine.

Advanced Imaging: When Are Scans Needed?

For a person with a history of migraine who develops classic, typical visual aura, imaging is often not necessary. However, a doctor may order an MRI (Magnetic Resonance Imaging) scan of the brain if there are any red flags, such as:

An aura that is atypical (e.g., lasts >60 minutes, includes weakness).
An aura that always occurs on the same side (side-locked).
A change in the pattern or frequency of established migraine attacks.
To rule out other structural causes like a tumour, stroke, or vascular malformation.

Emerging tools like Optical Coherence Tomography Angiography (OCTA) are revealing subtle differences in the fine blood vessels of the retina in people with migraine compared to controls, but this remains a research tool for now and is not used for routine diagnosis [¹² | Podraza et al., 2024, OCTA meta-analysis].

comparison of two OCTA scans (healthy control vs person with migraine)

[A comparison of two OCTA scans. The image on the left labelled “Healthy Control” shows a dense, uniform network of retinal capillaries. The image on the right labelled “Person with Migraine” shows areas of lower capillary density or “dropout as” highlighted by the arrows.AI generated image inspired from actual OCTA scans.”]

Managing Migraine with Visual Symptoms

Management in Adults

Managing migraine with visual symptoms (sometimes referred to as ocular migraine) generally follows the same evidence-based approach used for other types of migraine. This involves three key areas: maintaining healthy lifestyle habits, using acute treatments to stop an attack, and preventive therapies for people with frequent or disabling attacks. Lifestyle measures such as regular sleep, balanced meals, hydration, exercise, and stress management are the foundation of migraine care and can make a significant difference for many people.

For acute treatment, simple analgesics or NSAIDs may be effective for mild attacks, while triptans are commonly prescribed for moderate to severe migraine. Newer medications, including gepants, are emerging options—particularly for those who cannot take or do not respond to triptans. Preventive therapies may be considered if migraine attacks occur often or are highly disabling. Options include established oral medications (such as beta-blockers, anticonvulsants, or certain antidepressants), botulinum toxin for chronic migraine, and newer CGRP monoclonal antibodies that have shown strong effectiveness.

Because treatment choices depend on individual health factors and the availability of newer therapies in Australia continues to evolve, it is important to work closely with a healthcare professional to find the most suitable approach.

Paediatrics & Adolescents: A Specialised Approach

Treating children and teenagers requires special consideration, always under the guidance of a paediatrician or paediatric neurologist.

Foundation First: The primary focus is always on lifestyle management (sleep, diet, hydration, stress) and identifying triggers. Psychological support (like CBT) is highly effective.

Acute Treatment:

Analgesics: Ibuprofen is often the first-line choice, with good evidence for its efficacy in paediatric migraine. Paracetamol can also be used.
Triptans: Oral triptans may be used off-label by specialists. This is important to discuss with your doctor.

Preventive Treatment:

There is less high-quality evidence for preventive medications in children compared to adults.
Commonly used off-label options, prescribed by specialists, include propranolol, topiramate, and amitriptyline. Cyproheptadine is sometimes used in younger children.
The goal is to use the lowest effective dose for the shortest necessary time, with careful monitoring for side effects.

Latest Research and Future Directions

Unlocking the Secrets of Aura

Research continues to unravel the complex biology of aura. Scientists are using advanced imaging and electrophysiology to understand exactly how CSD starts, what makes it stop, and how it triggers the trigeminovascular system—the network of nerves and blood vessels responsible for the headache pain that often follows [⁴ | Viana et al., 2019, Visual aura review]. Understanding this link is key to developing treatments that can stop the entire migraine process at the aura stage.

Seeing the Signs: The Retina as a Window to Migraine

The eye may offer a unique window into the migraine brain. As mentioned, studies using OCTA are consistently finding subtle changes in the network of tiny blood vessels in the retina of people with migraine, even between attacks [¹² | Podraza et al., 2024, OCTA meta-analysis] [¹³ | Patzkó et al., 2024, Retinal neurovasculature]. While still a research tool, this could one day lead to a simple eye scan being used as a biomarker to help diagnose migraine or predict who might respond best to certain treatments.

Resources and Support (Australia)

Navigating migraine can be challenging, but you are not alone. Headache Australia provides extensive resources, support, and information for patients and their families.

General Migraine Information: https://headacheaustralia.org.au/migraine/

Information on Chronic Migraine: https://headacheaustralia.org.au/chronic-migraine/

Find a Headache Clinic: https://headacheaustralia.org.au/headache-management/headache-and-pain-clinics/

Find a Specialist Doctor: https://headacheaustralia.org.au/doctor-directory/

References

Headache Classification Committee of the International Headache Society (IHS). (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38(1), 1–211. https://doi.org/10.1177/0333102417738202
Hadjikhani, N., Sanchez Del Rio, M., Wu, O., et al. (2001). Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proceedings of the National Academy of Sciences, 98(8), 4687–4692. https://doi.org/10.1073/pnas.071582498
Friedman, D. I. (2019). The visual auras of migraine. Current Pain and Headache Reports, 23(11), 83. https://doi.org/10.1007/s11916-019-0822-7
Viana, M., Tronvik, E., Do, T. P., et al. (2019). Clinical features of visual migraine aura: A systematic review. The Journal of Headache and Pain, 20, 64. https://doi.org/10.1186/s10194-019-1008-x
Kim, K. M., Kim, B.-K., Lee, W., et al. (2022). Prevalence and impact of visual aura in migraine and probable migraine: A population study. Scientific Reports, 12, 456. https://doi.org/10.1038/s41598-021-04535-y
Thomsen, A. V., Christensen, C. E., Olesen, J., et al. (2024). Clinical features of migraine with aura: A REFORM study. The Journal of Headache and Pain, 25, 62. https://doi.org/10.1186/s10194-024-01718-1
Chong, Y. J., Gupta, V., Lamoureux, E. L., et al. (2021). Current perspective on retinal migraine pathophysiology and clinical management. Vision, 5(3), 38. https://doi.org/10.3390/vision5030038
Australian and New Zealand Living Clinical Guidelines for Stroke Management. (2022). Transient ischaemic attack (TIA)—medical emergency statement. Retrieved from https://informme.org.au/resources/transient-ischaemic-attack-tia
Pula, J. H., & Kattah, J. C. (2016). Transient monocular vision loss. Current Neurology and Neuroscience Reports, 16(8), 75. https://doi.org/10.1007/s11910-016-0673-5
Petzold, A., Bennett, J. L., Costello, F., et al. (2022). Diagnosis and classification of optic neuritis. The Lancet Neurology, 21(12), 1120–1134. https://doi.org/10.1016/S1474-4422(22)00200-9
Jeffery, R. C. H. (2021). Blackout: Understanding transient vision loss. Australian Journal of General Practice, 50(3). https://www1.racgp.org.au/ajgp/2021/march/blackout-understanding-transient-vision-loss
Podraza, W., Zaccara, V., Almendáriz-Muñoz, S., et al. (2024). Optical coherence tomography angiography in migraine: A systematic review and meta-analysis. Headache, 64(9), 1131–1146. https://doi.org/10.1111/head.14859
Patzkó, Á., Nagy, B. V., Szalai, E., et al. (2024). Neurovascular changes of the retina and optic nerve head in episodic migraine. Scientific Reports, 14, 20108. https://doi.org/10.1038/s41598-024-71388-1
Ashina, M., Katsarava, Z., Do, T. P., et al. (2021). Migraine: A narrative review. Nature Reviews Disease Primers, 7, 24. https://doi.org/10.1038/s41572-021-00256-y
Charles, A., Pozo-Rosich, P., Buse, D. C., et al. (2021). Diagnosis and management of migraine in ten steps. Nature Reviews Neurology, 17, 501–514. https://doi.org/10.1038/s41582-021-00509-5
Headache Australia. (2024). New treatments update. Retrieved from https://headacheaustralia.org.au/new-treatments-update/
Australian Prescriber (NPS MedicineWise). (2022). Calcitonin gene-related peptide (CGRP) antagonists for migraine. Australian Prescriber, 45(5), 164–167. https://doi.org/10.18773/austprescr.2022.051
Headache Australia. (2024). Headache & migraine diaries: tracking tools. Retrieved from https://headacheaustralia.org.au/headache-management/headache-migraine-diaries/
Pharmaceutical Benefits Scheme. (2024). Galcanezumab. Retrieved August 20, 2025, from https://www.pbs.gov.au/medicine/item/12874W
Pharmaceutical Benefits Scheme. (2024). Fremanezumab. Retrieved August 20, 2025, from https://www.pbs.gov.au/medicine/item/13132M
Pharmaceutical Benefits Scheme. (2024). Eptinezumab. Retrieved August 20, 2025, from https://www.pbs.gov.au/medicine/item/13352R
Pharmaceutical Benefits Advisory Committee. (2019). Public Summary Document—Fremanezumab. Retrieved from https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2019-11/fremanezumab
Pharmaceutical Benefits Scheme—Medicine Status Website. (2025). Erenumab. Retrieved August 20, 2025, from https://www.pbs.gov.au/medicinestatus/
Headache Australia. (2024). Calcitonin gene-related peptide (CGRP) therapies. Retrieved from https://headacheaustralia.org.au/calcitonin-gene-related-peptide-antibodies-for-migraine/
American Headache Society. (2021). The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache, 61(7), 1021-1039. https://doi.org/10.1111/head.14153
Austroads. (2022). Assessing Fitness to Drive for commercial and private vehicle drivers. Retrieved from https://austroads.com.au/publications/assessing-fitness-to-drive/ap-g56
Austroads. (2022). Vision and eye disorders—AFTD chapter. In Assessing Fitness to Drive. Retrieved from https://austroads.gov.au/publications/assessing-fitness-to-drive/ap-g56/vision-and-eye-disorders